Most of Japan's stock of syringes consists of regular versions that can draw just five doses from each vial, sparking fears that millions of doses could be wasted.
The EU has so far approved three vaccines -- Pfizer-BioNTech, Moderna and AstraZeneca-Oxford. Three other vaccines are under "rolling review" by the Amsterdam-based EMA -- Novavax, CureVac and Russia's Sputnik.
Health authorities added to the cautious optimism Monday when they announced that vaccinated people could meet together in small groups indoors without wearing masks or the need for social distancing.
Japan began its COVID-19 inoculation campaign last month, using Pfizer's vaccine. Taro Kono, the minister in charge of the effort, said on Friday that some shots may go to waste amid a shortage of the specialty syringes.
A week ago, Hungary became the first European Union member to start inoculating people with China's Sinopharm vaccine after rolling out Russia's Sputnik V vaccine as well, even though neither has been granted approval for emergency use by the bloc.
A new change is that it (AstraZeneca jab) can be given to everyone above the age of 18 without any age limit. There has been sufficient data that proves its efficacy also for older people.
“Our findings show a dramatic reduction in the rate of positive screening tests among asymptomatic healthcare workers after a single dose of the Pfizer-BioNTech vaccine,” said Nick Jones, an infectious diseases specialist at Cambridge University Hospital, who co-led the study.
Hassan's comments and pushback by other politicians added to anger in Lebanon, where decades of state waste and corruption have triggered a financial meltdown.
"You're a liar and a hypocrite, and you shouldn't stay in Lebanon," Ferzli shouted on live TV. Screenshots went viral among Lebanese on social media with captions such as "What I look like when I stub my toe" or "Vaccine side effect."
The Pfizer/BioNTech shot is the first vaccine against the novel coronavirus to receive full approval in Brazil, Anvisa said. Other vaccines developed by AstraZeneca and China's Sinovac Biotech Ltd, have only been approved for emergency use so far.
The approval is good news for a country whose immunization campaign has been plagued by delays and political squabbling.
The remarks put the United States on track to receive 240 million doses by the end of March, enough to inoculate 130 million Americans, and 700 million doses by mid-year.
However, the unresolved question of who would pay for claims for damages in the event of adverse effects from the inoculations has delayed the delivery.
Though concern has grown over variants of the virus, especially those that appear to spread more easily and render current shots less potent, Fauci sounded a hopeful note on whether another surge was coming.